Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
View Older Stories View More Recent Stories
-
Iovanace Biotherapeutics (IOVA) PT Raised to $33 at Chardan Capital Markets
-
UPDATE: Chardan Capital Markets Starts Rocket Pharmaceuticals (RCKT) at Buy, Sees Over 100% Upside
-
Krystal Biotech (KRYS) PT Raised to $90 at Chardan Capital Markets
-
Scienjoy To Become A Public Company Via Business Combination With Wealthbridge
-
Dicerna Pharmaceuticals (DRNA) PT Increases to $20 at Chardan on Cash Infusion
-
Chardan Healthcare Acquisition Corp. Completes Merger with BiomX Ltd.
-
Chardan Capital Markets Reiterates Buy Rating on CRISPR Therapeutics (CRSP)
-
Greenland Acquisition Corporation and Zhongchai Holding (Hong Kong) Limited Announce Closing of Business Combination
-
UPDATE: Chardan Capital Markets Starts PDS Biotechnology Corp (PDSB) at Buy
-
Form 8-K Chardan Healthcare Acqui For: Oct 23
-
Form DEFA14A Chardan Healthcare Acqui
-
Chardan Healthcare Acquisition Corp. Shareholders Approve Definitive Merger Agreement with BiomX Ltd.
-
Provention Bio Inc. (PRVB) PT Lowered to $18.50 at Chardan Capital Markets
-
PlacementTracker Publishes Q3 2019 PIPE and Private Placement Markets League Tables
-
Arrowhead Research (ARWR) PT Raised to $45 at Chardan Capital Markets After R&D Day
-
Form 8-K Chardan Healthcare Acqui For: Oct 21
-
ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Form 10-Q Chardan Healthcare Acqui For: Sep 30
-
Form 8-K Chardan Healthcare Acqui For: Oct 15
-
Form DEFA14A Chardan Healthcare Acqui
-
ProQR (PRQR) Prices 9.09M Share Offering at $5.50/Sh
-
ProQR Prices $50 Million Underwritten Public Offering of Ordinary Shares
-
Form 8-K Chardan Healthcare Acqui For: Oct 14
-
Form DEFA14A Chardan Healthcare Acqui
-
Kodiak Sciences Inc. (KOD) PT Raised to $35 at Chardan Capital Markets
-
Genius Brands (GNUS) Partners with Alibaba (BABA) for Co-Production Deal; PT Lowered to $4.50 at Chardan Capital Markets
-
Chardan Healthcare Acquisition (CHAC) Announces Amendment to Merger Agreement with BiomX Ltd.
-
Chardan Healthcare Acquisition Corp. Announces Amendment to Merger Agreement with BiomX Ltd.
-
Form 8-K Chardan Healthcare Acqui For: Oct 11
-
Form DEFA14A Chardan Healthcare Acqui
-
Form DEFA14A Chardan Healthcare Acqui
-
CORRECTING and REPLACING -- Chanticleer Holdings Announces Merger Agreement with Sonnet BioTherapeutics to Advance Pipeline of Novel Immune Therapeutics
-
CORRECTING and REPLACING -- Chanticleer Holdings Announces Merger Agreement with Sonnet BioTherapeutics to Advance Pipeline of Novel Immune Therapeutics
-
Chanticleer Holdings (BURG) Announces Merger Agreement with Sonnet BioTherapeutics
-
Chanticleer Holdings Announces Merger Agreement with Sonnet BioTherapeutics to Advance Pipeline of Novel Immune Therapeutics
-
Chanticleer Holdings Announces Merger Agreement with Sonnet BioTherapeutics to Advance Pipeline of Novel Immune Therapeutics
-
Chanticleer Holdings Announces Merger Agreement with Sonnet BioTherapeutics to Advance Pipeline of Novel Immune Therapeutics
-
American BriVision Appoints Chihliang "Andy" An as New Chief Financial Officer
-
American BriVision Appoints Chihliang "Andy" An as New Chief Financial Officer
-
Form DEFA14A Chardan Healthcare Acqui
-
Form 8-K Chardan Healthcare Acqui For: Oct 03
-
The Medicines Company to Participate in the Chardan 3rd Annual Genetic Medicines Conference
-
Chardan Capital Markets Downgrades Arbutus Biopharma (ABUS) to Neutral
-
MeiraGTx to Present at Upcoming Scientific and Investor Conferences
-
MeiraGTx to Present at Upcoming Scientific and Investor Conferences
-
Chardan Advises Health Sciences Acquisitions Corporation on Merger with Immunovant
-
AVROBIO, Inc. to Present at Chardan’s 3rd Annual Genetic Medicines Conference
-
Arcturus Therapeutics to Present at Three Upcoming Investor Conferences
-
Solid Biosciences to Participate in the Chardan 3rd Annual Genetic Medicines Conference
-
Immunovant to Merge with Health Sciences Acquisitions Corporation, Creating New Publicly Listed FcRn-Focused Company

